Contact this trialFirst, we need to learn more about you.
CDK4/6 Inhibitor
Osimertinib + Abemaciclib for Non-Small Cell Lung Cancer after Osimertinib Resistance
Recruiting3 awardsPhase 2
La Jolla, California
This trial will explore a new strategy to treat patients with EGFR mutated lung cancer who have developed resistance to osimertinib.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service